See referenced original article on pages 740–8, this issue.
Cytokine polymorphisms and hepatocellular carcinoma†
To B or not to B
Article first published online: 7 JAN 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 4, pages 654–656, 15 February 2005
How to Cite
Chung, R. T. (2005), Cytokine polymorphisms and hepatocellular carcinoma. Cancer, 103: 654–656. doi: 10.1002/cncr.20837
Fax: (617) 726-5895
- Issue published online: 3 FEB 2005
- Article first published online: 7 JAN 2005
- Manuscript Accepted: 26 OCT 2004
- Manuscript Received: 18 OCT 2004
Regardless of whether monitoring practices change as a result of genotyping, the mandate that replicative hepatitis B virus disease must be treated because of the long-term risk for necroinflammatory disease, fibrosis, cirrhosis, and hepatocellular carcinoma remains firmly in place.
See also pages 740–8.